One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling
- Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trials
- Proceeds will also help scale strategic partnerships with pharmaceutical and biotechnology companies
- Financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures
Paris, France – July 17, 2025 – One Biosciences (“One Biosciences” or the “Company”), a precision oncology techbio company pioneering clinical grade single-cell tumor transcriptomic profiling, today announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding, to date, to over €20 million including Home Biosciences’ seed financing.
